How to Help Your Patients Save Money on Synarel: A Provider's Guide to Savings Programs

Synarel (nafarelin acetate) is one of the most expensive GnRH agonist options available in the United States. At $3,100–$3,500 per bottle (cash price), with no generic equivalent and no biosimilar on the horizon, cost-related non-adherence is a real clinical risk for your patients. A patient who can't afford their medication will miss doses — or stop treatment altogether — often without telling you.

As the prescribing provider, you are in the best position to connect patients with cost reduction resources before they hit the financial wall. This guide covers every program, strategy, and workflow your office can use to reduce the cost burden of Synarel for your patients.

Understanding the Cost Landscape for Synarel in 2026

Cash price: $3,100–$3,500 per 8 mL bottle. At the endometriosis dose (400 mcg/day), this equates to $3,100–$3,500 per month. At the CPP dose (1,600 mcg/day), patients may need 4 bottles per month — approaching $12,000–$14,000 monthly in cash cost.

With insurance: Most plans cover Synarel with prior authorization. Specialty drug tier copays typically range from $50–$200 per month for insured patients, depending on the plan. Some patients with high-deductible plans will pay full price until their deductible is met.

Uninsured or underinsured: These patients need your help most. Without a patient assistance program or discount program, the cash cost is prohibitive for most patients.

Program 1: Pfizer's Patient Assistance Program (RxPathways)

Pfizer offers financial assistance for Synarel through its RxPathways program. Eligible patients may receive the medication at no cost. As the prescribing provider, you can directly facilitate enrollment:

Eligibility criteria: Based on income, insurance status, and US residency. Uninsured and underinsured patients are typically prioritized.

Provider role: Your office may need to provide a signature or letter of medical necessity as part of the application process.

Contact: Call 866-706-2400 or direct patients to pparx.org to initiate enrollment.

Consider adding a brief screening question at intake or during medication prescribing visits: "Are you concerned about your ability to afford this medication?" This opens the conversation without patients having to volunteer financial hardship.

Program 2: Insurance Prior Authorization — Optimizing for Approval

For insured patients, the highest-impact action your office can take is submitting a complete and well-documented prior authorization at the time of prescribing. Incomplete PAs are the most common cause of coverage delays and denials.

For endometriosis PAs, include:

ICD-10 diagnosis code (N80.x for endometriosis, specific to site if possible)

Documentation of prior treatment with OCs, progestins, or NSAIDs and reason for inadequacy (if step therapy required)

Expected treatment duration (6 months or less)

Specialist status (OB/GYN, REI)

For CPP PAs, include:

Confirmed CPP diagnosis with pubertal LH levels or GnRH stimulation test results

Bone age x-ray and comparison to chronological age

Age at onset of secondary sexual characteristics

Pediatric endocrinologist involvement notation

Program 3: Copay Cards and GoodRx Coupons for Insured Patients

Even insured patients may face significant specialty tier copays. GoodRx and SingleCare provide coupons that some patients can use to reduce out-of-pocket cost — though note that these are generally used when paying cash, not on top of insurance. Patients on high-deductible plans may benefit from using a GoodRx coupon until their deductible is met.

Direct patients to GoodRx.com and have them enter their zip code along with "Synarel" to compare current prices at pharmacies in their area.

Program 4: Consider Cost-Effective Alternatives for Appropriate Patients

If a patient cannot access Synarel due to cost, a clinical pivot may be warranted. Generic leuprolide acetate (generic Lupron) is significantly less expensive than brand-name Synarel — and may be more accessible. The tradeoff is a shift to injectable dosing (monthly IM injection) rather than a twice-daily nasal spray.

For endometriosis patients, elagolix (Orilissa) is also an option — an oral daily pill. Orilissa has its own cost considerations, but it has a manufacturer copay assistance program and may be more accessible on some formularies.

Frame the conversation with patients: "There is a less expensive alternative that works through the same mechanism. Would you like me to discuss it as an option?" Most patients appreciate this proactive approach.

Program 5: State and Federal Assistance Programs

For patients who are uninsured or have Medicaid coverage, additional programs may be available:

State Pharmaceutical Assistance Programs (SPAPs) — available in some states for low-income patients

NeedyMeds.org — searchable database of patient assistance programs by drug name

Hill-Burton free or reduced-cost healthcare programs for eligible patients at federally-funded facilities

Building Cost Counseling Into Your Prescribing Workflow

The most effective way to prevent cost-driven non-adherence is to address cost proactively — before you send the patient to the pharmacy. Consider these practical workflow additions:

At every new prescription: ask patients directly if they have any concerns about affording the medication

Train your MA or front desk staff to hand out a "Synarel cost resources" one-pager with PAP contact info and GoodRx instructions

Set up an internal workflow to submit PAs proactively — not reactively

Document patient-reported cost concerns in the chart and flag for follow-up

To address both access and cost issues simultaneously, consider directing patients to medfinder — which calls pharmacies to compare which ones have Synarel in stock and can fill it, helping patients find the most accessible option.

For a broader look at the clinical context, read our Synarel shortage and access update for providers.